Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Tuesday, January 13, 2015

Alisporivir program rights returned to Debiopharm

Debiopharm Group has regained all rights to Alisporivir, a cyclophilin inhibitor being investigated for the treatment of hepatitis C virus infection, as a result of a new agreement between the pharmaceutical company and Novartis, according to a news release from the company.

Alisporivir (DEB025, Debiopharm) is currently undergoing two phase 2 clinical trials of therapy without interferon for HCV, and has already been tested in over 2,000 patients, according to the release.

The release stated that Debiopharm and Novartis entered into a partnership for the development of alisporivir in January 2010, which allowed for the current transfer of ongoing alisporivir phase 2 clinical trials to Debiopharm. The new agreement also transfers all rights for HCV and other indications for the drug.

Read more...
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)